Skip to content
DataLookout
Menu

NCT07885436

68Ga-XHER2 PET/CT for HER2 Assessment

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Evaluate the feasibility of PET/CT imaging with 68Ga-XHER2 for the non-invasive assessment of HER2 expression in various cancer types.
Timeframe: 1month

Secondary (1)

Description of 68Ga-XHER2 uptake by measuring standardized uptake value (SUV) in various types of tumors

Arms and interventions

68Ga-XHER2Experimental

Each subject receives a single intravenous injection of 68Ga-XHER2 and undergoes PET/CT imaging within the specified time.

Drugs: 68Ga-XHER2 PET/CT

Sites

1 site in 1 country

  • The First Affiliated Hospital of Xiamen UniversityXiamen, Fujian, China